Cortex Plans To Move CX717 Ahead In Other Indications Despite FDA Rejection For ADHD Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency denies Cortex investigational new drug application for a Phase IIb study of Ampakine compound CX717 in ADHD.
You may also be interested in...
Cortex To Resume CX717 Alzheimer Study, Initiate ADHD Trial
Announcement comes after FDA approves a study protocol with higher doses of the Ampakine compound.
Cortex To Pursue CX717 In Alzheimer's Under FDA Dosing Restrictions
The company will not pursue an ADHD indication until further toxicological data show an increased safety margin for higher doses.
Cortex’ Plan For Clinical Hold Lift Approved By FDA
The firm will submit additional preclinical data in September on the ADHD therapy CX717.